Illumina, Inc. (0J8Z.L)
USD 137.9
(-3.76%)
USD 137.9
(-3.76%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.81 Billion USD | 7.72% |
| 2022 | 2.61 Billion USD | -20.11% |
| 2021 | 3.27 Billion USD | 101.91% |
| 2020 | 1.62 Billion USD | 9.51% |
| 2019 | 1.48 Billion USD | 4.59% |
| 2018 | 1.41 Billion USD | 16.15% |
| 2017 | 1.22 Billion USD | 12.19% |
| 2016 | 1.08 Billion USD | 17.41% |
| 2015 | 926.18 Million USD | 8.41% |
| 2014 | 854.33 Million USD | 29.88% |
| 2013 | 657.78 Million USD | 27.23% |
| 2012 | 517.01 Million USD | 3.28% |
| 2011 | 500.58 Million USD | 28.39% |
| 2010 | 389.88 Million USD | 20.47% |
| 2009 | 323.63 Million USD | 23.3% |
| 2008 | 262.48 Million USD | 13.06% |
| 2007 | 232.17 Million USD | 165.55% |
| 2006 | 87.43 Million USD | 56.22% |
| 2005 | 55.96 Million USD | 30.65% |
| 2004 | 42.83 Million USD | -4.0% |
| 2003 | 44.62 Million USD | -7.73% |
| 2002 | 48.35 Million USD | 49.96% |
| 2001 | 32.24 Million USD | 29.29% |
| 2000 | 24.94 Million USD | 284.4% |
| 1999 | 6.48 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 237 Million USD | -67.36% |
| 2024 Q3 | 492 Million USD | 107.59% |
| 2024 Q1 | 726 Million USD | -0.82% |
| 2023 Q4 | 732 Million USD | 18.45% |
| 2023 FY | 2.82 Billion USD | 7.72% |
| 2023 Q1 | 719 Million USD | -7.58% |
| 2023 Q2 | 808 Million USD | 12.38% |
| 2023 Q3 | 618 Million USD | -23.51% |
| 2022 Q4 | 778 Million USD | 65.18% |
| 2022 FY | 2.61 Billion USD | -20.11% |
| 2022 Q1 | 631 Million USD | -18.69% |
| 2022 Q2 | 737 Million USD | 16.8% |
| 2022 Q3 | 471 Million USD | -36.09% |
| 2021 Q3 | 1.31 Billion USD | 113.82% |
| 2021 Q4 | 776 Million USD | -40.99% |
| 2021 FY | 3.27 Billion USD | 101.91% |
| 2021 Q1 | 571 Million USD | 14.66% |
| 2021 Q2 | 615 Million USD | 7.71% |
| 2020 Q3 | 364 Million USD | 9.64% |
| 2020 Q4 | 498 Million USD | 36.81% |
| 2020 Q1 | 430 Million USD | 9.14% |
| 2020 Q2 | 332 Million USD | -22.79% |
| 2020 FY | 1.62 Billion USD | 9.51% |
| 2019 Q4 | 394 Million USD | 15.88% |
| 2019 FY | 1.48 Billion USD | 4.59% |
| 2019 Q3 | 340 Million USD | -7.61% |
| 2019 Q2 | 368 Million USD | -3.16% |
| 2019 Q1 | 380 Million USD | -3.31% |
| 2018 Q4 | 393 Million USD | 10.39% |
| 2018 Q3 | 356 Million USD | 2.3% |
| 2018 FY | 1.41 Billion USD | 16.15% |
| 2018 Q1 | 320 Million USD | 2.56% |
| 2018 Q2 | 348 Million USD | 8.75% |
| 2017 Q1 | 308 Million USD | 11.59% |
| 2017 Q3 | 301 Million USD | 0.67% |
| 2017 Q4 | 312 Million USD | 3.65% |
| 2017 FY | 1.22 Billion USD | 12.19% |
| 2017 Q2 | 299 Million USD | -2.92% |
| 2016 Q1 | 273.22 Million USD | 4.45% |
| 2016 Q2 | 273.12 Million USD | -0.04% |
| 2016 FY | 1.08 Billion USD | 17.41% |
| 2016 Q3 | 265.06 Million USD | -2.95% |
| 2016 Q4 | 276 Million USD | 4.13% |
| 2015 FY | 926.18 Million USD | 8.41% |
| 2015 Q3 | 235.87 Million USD | 6.91% |
| 2015 Q4 | 261.59 Million USD | 10.91% |
| 2015 Q1 | 208.08 Million USD | -21.51% |
| 2015 Q2 | 220.62 Million USD | 6.02% |
| 2014 Q1 | 186.61 Million USD | -0.94% |
| 2014 Q2 | 197.63 Million USD | 5.91% |
| 2014 Q3 | 204.97 Million USD | 3.71% |
| 2014 FY | 854.33 Million USD | 29.88% |
| 2014 Q4 | 265.12 Million USD | 29.35% |
| 2013 Q1 | 146.52 Million USD | 7.25% |
| 2013 Q3 | 166.57 Million USD | 6.57% |
| 2013 Q4 | 188.37 Million USD | 13.09% |
| 2013 FY | 657.78 Million USD | 27.23% |
| 2013 Q2 | 156.3 Million USD | 6.68% |
| 2012 FY | 517.01 Million USD | 3.28% |
| 2012 Q4 | 136.62 Million USD | -7.24% |
| 2012 Q1 | 127.04 Million USD | -7.05% |
| 2012 Q3 | 147.27 Million USD | -0.66% |
| 2012 Q2 | 148.26 Million USD | 16.71% |
| 2011 Q2 | 122.57 Million USD | 3.31% |
| 2011 Q4 | 136.67 Million USD | 11.16% |
| 2011 FY | 500.58 Million USD | 28.39% |
| 2011 Q3 | 122.94 Million USD | 0.3% |
| 2011 Q1 | 118.65 Million USD | 11.32% |
| 2010 Q2 | 97.33 Million USD | 3.6% |
| 2010 Q3 | 99.81 Million USD | 2.54% |
| 2010 Q4 | 106.58 Million USD | 6.79% |
| 2010 FY | 389.88 Million USD | 20.47% |
| 2010 Q1 | 93.95 Million USD | 2.67% |
| 2009 Q4 | 91.5 Million USD | 17.06% |
| 2009 Q2 | 76.72 Million USD | -0.65% |
| 2009 Q1 | 77.22 Million USD | 10.01% |
| 2009 FY | 323.63 Million USD | 23.3% |
| 2009 Q3 | 78.17 Million USD | 1.88% |
| 2008 Q4 | 70.19 Million USD | 0.81% |
| 2008 Q2 | 65.84 Million USD | 15.92% |
| 2008 Q3 | 69.63 Million USD | 5.75% |
| 2008 FY | 262.48 Million USD | 13.06% |
| 2008 Q1 | 56.8 Million USD | -46.04% |
| 2007 Q4 | 105.27 Million USD | 135.4% |
| 2007 Q3 | 44.72 Million USD | 6.12% |
| 2007 Q2 | 42.14 Million USD | 5.28% |
| 2007 FY | 232.17 Million USD | 165.55% |
| 2007 Q1 | 40.03 Million USD | 68.62% |
| 2006 Q3 | 21.86 Million USD | 1.79% |
| 2006 FY | 87.43 Million USD | 56.22% |
| 2006 Q4 | 23.74 Million USD | 8.59% |
| 2006 Q2 | 21.47 Million USD | 5.54% |
| 2006 Q1 | 20.35 Million USD | 29.22% |
| 2005 Q1 | 11.92 Million USD | 51.2% |
| 2005 Q2 | 13.83 Million USD | 16.0% |
| 2005 Q3 | 14.45 Million USD | 4.47% |
| 2005 Q4 | 15.74 Million USD | 8.95% |
| 2005 FY | 55.96 Million USD | 30.65% |
| 2004 Q2 | 11.75 Million USD | 2.9% |
| 2004 Q4 | 7.88 Million USD | -33.0% |
| 2004 Q3 | 11.77 Million USD | 0.2% |
| 2004 Q1 | 11.42 Million USD | 2.72% |
| 2004 FY | 42.83 Million USD | -4.0% |
| 2003 Q3 | 10.91 Million USD | -2.89% |
| 2003 Q4 | 11.11 Million USD | 1.92% |
| 2003 FY | 44.62 Million USD | -7.73% |
| 2003 Q1 | 11.35 Million USD | -86.5% |
| 2003 Q2 | 11.23 Million USD | -1.07% |
| 2002 Q3 | -8.98 Million USD | -149.52% |
| 2002 FY | 48.35 Million USD | 49.96% |
| 2002 Q2 | 18.13 Million USD | 82.11% |
| 2002 Q1 | 9.95 Million USD | 5.72% |
| 2002 Q4 | 84.13 Million USD | 1036.81% |
| 2001 Q1 | 7.24 Million USD | -2.09% |
| 2001 FY | 32.24 Million USD | 29.29% |
| 2001 Q4 | 9.42 Million USD | 21.24% |
| 2001 Q3 | 7.77 Million USD | -1.45% |
| 2001 Q2 | 7.88 Million USD | 8.86% |
| 2000 FY | 24.94 Million USD | 284.4% |
| 2000 Q3 | 6.21 Million USD | 5.3% |
| 2000 Q1 | 5.42 Million USD | 0.0% |
| 2000 Q2 | 5.9 Million USD | 8.93% |
| 2000 Q4 | 7.39 Million USD | 18.95% |
| 1999 FY | 6.48 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -1441.827% |
| Dynavax Technologies Corporation | 219.14 Million USD | -1639.944% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -620.779% |
| Perrigo Company plc | 1.52 Billion USD | -149.46% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 62.815% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -745.468% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 90.608% |
| IQVIA Holdings Inc. | 2.05 Billion USD | -85.728% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -3060.198% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | -35.438% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -8436.503% |
| Waters Corporation | 943.51 Million USD | -304.126% |
| Biogen Inc. | 5.2 Billion USD | 26.742% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -1567.395% |
| Evolus, Inc. | 189.75 Million USD | -1909.391% |
| Adicet Bio, Inc. | 152.03 Million USD | -2407.926% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -2576.484% |
| bluebird bio, Inc. | 240.23 Million USD | -1487.216% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -1302.369% |
| FibroGen, Inc. | 398.11 Million USD | -857.768% |
| Agilent Technologies, Inc. | 2.11 Billion USD | -80.284% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -27312.641% |
| Homology Medicines, Inc. | 9.87 Million USD | -38512.658% |
| Geron Corporation | 70.44 Million USD | -5313.041% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -111.826% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -791.615% |
| Myriad Genetics, Inc. | 600.1 Million USD | -535.394% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -3681.725% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -591.304% |
| Zoetis Inc. | 2.76 Billion USD | -37.902% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -7761.531% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -250.012% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -118.35% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 20.147% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -9638.717% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -389.105% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -1283.06% |
| Verastem, Inc. | 92.08 Million USD | -4040.785% |
| Nektar Therapeutics | 190.9 Million USD | -1897.349% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -700.445% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -31305.98% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -180.199% |
| OPKO Health, Inc. | 574.68 Million USD | -563.493% |
| Exelixis, Inc. | 1.58 Billion USD | -140.299% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -138.835% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -934.421% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -6738.726% |
| uniQure N.V. | 285.08 Million USD | -1237.491% |
| Imunon, Inc. | 21.03 Million USD | -18030.87% |
| Blueprint Medicines Corporation | 722.86 Million USD | -427.487% |
| Insmed Incorporated | 949.26 Million USD | -301.681% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -1173.896% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -832.716% |
| TG Therapeutics, Inc. | 198.47 Million USD | -1821.149% |
| Incyte Corporation | 1.19 Billion USD | -220.287% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -265.23% |